医学分子生物学杂志 ›› 2024, Vol. 21 ›› Issue (3): 196-202.doi: 10.3870/j.issn.1672-8009.2024.03.002

• 论著 • 上一篇    下一篇

RIPK3 LPS / D-GalN 诱导急性肝衰竭中的作用研究 #br#

  

  1. 南京医科大学上海松江临床医学院 上海市, 201615
  • 出版日期:2024-05-31 发布日期:2024-06-14
  • 基金资助:
    国家自然科学基金 (No. 81770612)

Role of RIPK3 in LPS / D-GalN Induced Acute Liver Failure #br#

  1. Shanghai Songjiang Clinical Medical College of Nanjing Medical University, Shanghai, 201615, China

  • Online:2024-05-31 Published:2024-06-14

摘要: 目的 研究受体相互作用蛋白激酶 3 ( receptor-interacting protein kinases 3, RIPK3) 在脂多糖(lipopolysaccharide, LPS) / D-氨基半乳糖 ( D-galactosamine, D-GalN) 诱导的急性肝衰竭 ( acute liver failure, ALF) 中的作用方法 体内实验使用 SPF 级雄性 BALB / c 小鼠 15 , 随机分为对照组 ( Control),模型组 (LPS / D-GalN), 抑制剂预处理组 ( GSK872 + LPS / D-GalN), 每组 5 。 ALF 动物模型采用 LPS 联合 D-GalN 腹腔注射的方式制备药物腹腔注射前1 h, 分别以0. 1 % DMSO RIPK3 特异性拮抗剂 GSK872(溶于 0. 1 % DMSO) 尾静脉注射进行预处理肝损伤程度采用血生化检测和肝脏组织学变化来评估; 基因mRNA 表达采用 PCR 检测, 蛋白表达采用蛋白质印迹和免疫组化分析结果 动物实验结果显示, 与正常对照组 (Control) 相比, 模型组 ( LPS / D-GalN) 小鼠肝组织见显著炎症出血坏死性损伤, 肝内 F4 / 80 + 细胞浸润增多, 血清 ALT AST 水平明显升高 ( P< 0. 01)。 同时, 肝组织 F4 / 80、 Mcp-1、 Tnf-αIl-6、Ripk3 Mlkl mRNA, 以及 RIPK3 蛋白和 p-MLKL / MLKL 蛋白比值均上调, 差异均存在统计学意义 ( P<0. 05)。 与模型组相比, 预处理组 (GSK872 + LPS / D-GalN) 小鼠肝脏炎症损伤程度明显减轻, 肝内 F4 / 80 +细胞浸润明显减少, 且血清 ALT AST 水平显著下降 ( P< 0. 01)。 肝组织 F4 / 80、 Mcp-1、 Tnf-αIl-6、Ripk3 Mlkl mRNA, 以及 RIPK3 蛋白和 p-MLKL / MLKL 蛋白比值下调, 差异均有统计学意义 ( P<0. 05)。 结论 LPS / D-GalN 联合诱导的小鼠急性肝衰竭模型中, RIPK3 抑制剂的应用可能直接通过靶向肝细胞, 减少肝细胞的坏死性凋亡, 从而减少巨噬细胞浸润, 最终改善肝脏炎症状态这提示 RIPK3 可能通过对肝细胞坏死性凋亡通路分子的影响促进 ALF 的发生和发展

关键词: 急性肝衰竭, 坏死性凋亡, 肝细胞, 受体相互作用蛋白激酶 3

Abstract: Objective To study the role of receptor-interacting protein kinase 3 ( RIPK3) in acute liver failure induced by lipopolysaccharide / D-galactosamine (LPS / D-GalN). Methods SPFgrade male BALB / c mice were randomly divided into 3 groups (n = 5). The ALF animal model wasestablished by intraperitoneal injection of LPS combined with D-GalN. One hour before intraperitoneal drug injection, the mice were pretreated with intravenous injections of 0. 1 % DMSO and the RIPK3-specific antagonist GSK872 (dissolved in 0. 1 % DMSO), respectively. The degree of liver injury was assessed by blood biochemical tests and histological changes in the liver tissue. PCR was used to detect the expression levels of mRNA, while Western blotting and immunohistochemistrywas used to detect the expression levels of proteins. Results Animal experimental results showedthat LPS / D-GalN-challenged mice exhibited significant inflammatory hemorrhagic necrotic damageand increased infiltration of F4 / 80 + cells in liver tissues, and a notable elevation of ALT and AST levels in blood (both P < 0. 01) when compared with the control. In addition, the mRNA levels of F4 / 80, Mcp-1, Tnf-α, Il-6, Ripk3 and Mlkl, as well as the levels of RIPK3 protein and pMLKL / MLKL protein ratio, were all upregulated in liver tissues in comparison with the controlgroup, with all differences being statistically significant ( all P < 0. 05). Compared to the mice in the LPS / D-GalN group, the GSK872-pretreated mice displayed a marked reduction in the degree ofliver inflammatory injury, a significant decrease in the infiltration of F4 / 80 + cells in the liver, anda substantial decline in serum ALT and AST levels (both P < 0. 01). The mRNA levels of F4 / 80,Mcp-1, Tnf-α, Il-6, Ripk3, and Mlkl as well as the levels of RIPK3 protein and p-MLKL / MLKLprotein ratio, were all downregulated in liver tissues, with all differences being statistically significant (all P< 0. 05). Conclusion The RIPK3 inhibitor GSK872 can significantly block the expression of RIPK3 in LPS / D-GalN-induced ALF in mice, mitigate liver tissue damage and inflammatorycell infiltration, and suppress the expression of necroptosis-related proteins. This suggests thatRIPK3 might promote the pathogenesis of ALF by influencing the molecules of the hepatic necroptotic apoptosis pathway.

Key words: acute liver failure, necroptosis, hepatocytes, receptor-interacting protein kinase 3

中图分类号: